Nouscom
eDR28Effective DR: 28/100. Bottom 25%. Measured by StartupHub.ai. Median 68.Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies
About
Founded in 2015, Nouscom is a clinical-stage BioTech company innovating next-generation neoantigen-targeted immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease. Its proprietary viral vector platform enables broad and durable immune activation by delivering optimised neoantigens that train the immune system to recognise and fight cancer.
Key facts
At-a-glance profile data
- Website
- nouscom.com
- Headquarters
- Basel, Switzerland
- Founded
- 2015
- Total funding
- $130M (Series D)
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Oct 2026 | Series D | $130M | M-Ventures |
Tech stack
Detected on nouscom.com, last scanned 19 Oct 2026. Run your own scan
- Hosting
- Google Cloud
Frequently asked
Is Nouscom trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Nouscom is 77 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Nouscom raised?
Nouscom has raised a total of $130M in funding. The most recent round on record is Series D.